Energy, Cognition & Mood
Peptides for 'Adrenal Fatigue' & Stress Burnout: Evidence vs Hype
A clinical-editorial breakdown of the peptides marketed for 'adrenal fatigue,' stress and burnout — starting from the fact that 'adrenal fatigue' is not a recognized diagnosis, then grading Selank, DSIP and thymosin alpha-1 honestly against human, animal and absent evidence.
Adrenal fatigueSelankDSIPStress & cortisolHPA axis
The quick verdict
'Adrenal fatigue' is not a recognized diagnosis, so no peptide has human evidence for it — but the adjacent territory of stress, anxiety and asthenia can be graded honestly. Here are the three peptides marketed for it, ranked by real evidence.
- Best overall
- Selank — The only candidate with controlled human trials — anxiolytic comparable to a benzodiazepine in GAD plus an antiasthenic (anti-fatigue) effect, graded B for anxiety/asthenia (not 'adrenal fatigue').
- Best value
- None (treat the real cause first) — No peptide is proven for 'adrenal fatigue' and none is FDA-approved; the highest-value step is having persistent fatigue evaluated for real, treatable disease rather than buying a research-chemical vial.
- Best for Diagnosed anxiety with a fatigue component (under clinician care)
- Selank — Its only genuine human evidence is in diagnosed anxiety and asthenia — comparable to a benzodiazepine without sedation or dependence in small Russian trials — not in healthy stressed adults or 'burnout.'
How we evaluated
We graded each peptide strictly by the strength of evidence for the legitimate target (stress, anxiety, asthenia and HPA-axis physiology), never for the unvalidated construct of 'adrenal fatigue.' Human controlled trials outrank animal data, which outranks mechanism-only or absent evidence, and we separate those tiers explicitly. All citations are primary where available (PubMed, PMC, the Endocrine Society) and were verified against the source literature.
- Human evidence quality. Controlled human trials (RCT or comparative) outrank open-label or single-region studies, which outrank animal or in-vitro data, which outrank mechanism-only or absent evidence.
- Specificity to the indication. Whether the data actually studied stress, anxiety, asthenia, cortisol or the HPA axis — versus a different endpoint (e.g. anxiety vs. 'burnout' vs. immune function) extrapolated by marketing.
- Honesty of the claim. Whether the human evidence confirms the marketed mechanism (e.g. DSIP 'lowers cortisol') or contradicts it, and whether preclinical signals failed to transfer to humans.
- Safety & regulatory status. Tolerability in published trials, FDA approval and 503A/PCAC standing, and WADA prohibited-list exposure.
Rating scale: 1–5 stars reflecting strength of human evidence for the legitimate target (stress/anxiety/asthenia/HPA), not popularity. Evidence grades: A = human RCTs/meta-analyses; B = human evidence below RCT level; C = preclinical only; D = anecdotal, mechanism-only, or unstudied for the indication.
Last verified .
At a glance
| # | Name | Evidence | Rating | Best for | Pricing |
|---|---|---|---|---|---|
| 1 | Selank | B | 3.0 | Understanding the single best-evidenced candidate — for diagnosed anxiety/asthenia under clinician care, not 'adrenal fatigue' | Prescription abroad (RU/UA); not FDA-approved |
| 2 | DSIP (Delta Sleep-Inducing Peptide / Emideltide) | C | 1.5 | Seeing how an animal cortisol effect can fail to transfer to humans — a cautionary case, not a recommendation | Not FDA-approved; research-chemical supply only |
| 3 | Thymosin Alpha-1 (Tα1 / thymalfasin) | D | 1.0 | Recognizing a peptide that does NOT belong on a stress or 'adrenal fatigue' list | Not FDA-approved (sold abroad as thymalfasin/Zadaxin) |
Selank
The only candidate with genuine human anxiolytic and anti-fatigue data
Selank is a synthetic heptapeptide derivative of the endogenous tetrapeptide tuftsin (TP-7), developed in Russia and approved there (and in Ukraine) as a prescription 0.15% intranasal spray for generalized anxiety disorder; it is not FDA-approved. It is the only peptide on this list with controlled human trials. In a randomized comparative trial, 62 patients with GAD and neurasthenia received either Selank or the benzodiazepine medazepam over roughly 14 days: anxiolytic efficacy on the Hamilton, Zung and CGI scales was comparable between the drugs, but Selank additionally showed an antiasthenic (anti-fatigue) and mild psychostimulant effect without sedation, cognitive impairment or dependence. A resting-state fMRI study in 52 healthy adults found Selank altered right-amygdala functional connectivity versus placebo, corroborating a real central anxiolytic action. The proposed mechanism is modulation of the GABAergic system by a route distinct from the benzodiazepine binding site, plus inhibition of enkephalin-degrading enzymes and serotonergic effects. Crucially, none of these trials studied 'adrenal fatigue,' cortisol normalization, burnout, or fatigue as a primary endpoint in healthy people — they studied diagnosed anxiety disorders. That earns it Grade B for stress/anxiety/asthenia, not the multi-RCT A tier, and not a 'burnout cure' claim.
Strengths
- Only peptide here with controlled human trials (anxiolytic comparable to a benzodiazepine in GAD)
- Documented antiasthenic (anti-fatigue) effect — the closest any candidate comes to a stress-burnout claim
- fMRI evidence of a real central effect (right-amygdala connectivity change) in 52 adults
- Well tolerated in trials with no sedation, dependence or withdrawal noted
Weaknesses
- Evidence is small, single-region (Russian) and unreplicated by any Western RCT or placebo-controlled GAD trial in the English literature
- Never studied for 'adrenal fatigue,' cortisol, or fatigue in healthy stressed adults — only diagnosed anxiety
- Not FDA-approved; interaction data with SSRIs/SNRIs/MAOIs are lacking and long-term safety is unstudied
- Best for
- Understanding the single best-evidenced candidate — for diagnosed anxiety/asthenia under clinician care, not 'adrenal fatigue'
- Pricing
- Prescription abroad (RU/UA); not FDA-approved
DSIP (Delta Sleep-Inducing Peptide / Emideltide)
Animal cortisol effects that failed the one controlled human test
DSIP is a naturally occurring nonapeptide first isolated from rabbit cerebral blood in 1977 and named for inducing delta-wave (deep) sleep on EEG; it is found in the hypothalamus, limbic system and pituitary. Its stress reputation rests almost entirely on animal data: in rodent stress models DSIP attenuated stress-induced corticosterone elevation, reduced stress-ulcer formation and normalized disrupted circadian hormone rhythms, and it has been described as a corticotropin-release-inhibiting factor in vitro and in vivo. That preclinical story is the entire basis for the 'DSIP lowers cortisol and calms the stress axis' marketing. The decisive human test contradicts it. In healthy young men, intravenous DSIP (3–4 mg) versus placebo around human-CRH injections produced almost identical ACTH and cortisol responses, and DSIP also failed to affect meal-related ACTH and cortisol surges; the authors concluded the data do not support an inhibitory role of DSIP on ACTH and cortisol secretion in man. Older small human reports describe normalized sleep in alcohol-withdrawal and reduced subjective fatigue, but these were small, decades-old and unreplicated under modern standards. The proposed HPA/cortisol-calming mechanism — the one that would justify a stress-burnout use — is the specific thing a controlled human study failed to confirm. It earns Grade C overall (preclinical), dropping to D for the specific human cortisol claim.
Strengths
- Consistent rodent evidence for blunting stress-induced corticosterone and normalizing hormone rhythms
- Plausible mechanistic rationale as a corticotropin-release-inhibiting factor in vitro/in vivo
- A thin, suggestive human niche in sleep architecture (its original named effect)
Weaknesses
- The one controlled human test found NO reduction in ACTH or cortisol — the central marketed claim is contradicted in people
- Human safety data are limited to small, short, decades-old studies with no controlled long-term profile
- DSIP/Emideltide is among the peptides queued for FDA PCAC review (July 24, 2026); not FDA-approved
- Best for
- Seeing how an animal cortisol effect can fail to transfer to humans — a cautionary case, not a recommendation
- Pricing
- Not FDA-approved; research-chemical supply only
Thymosin Alpha-1 (Tα1 / thymalfasin)
An immune peptide with zero stress, fatigue or HPA evidence
Thymosin alpha-1 is a 28-amino-acid immune-modulating peptide (marketed as thymalfasin or Zadaxin abroad) used in some countries as an immune adjuvant in chronic hepatitis and as a general immunomodulator. It appears on 'energy' and 'adrenal' peptide lists, but its presence there is category drift from broad 'vitality/immune optimization' marketing rather than any stress-specific data. The evidence for stress, burnout or fatigue is essentially none: targeted searching returns no direct human or animal evidence linking thymosin alpha-1 to chronic fatigue, the HPA axis or cortisol, and its established research base is immunological — T-cell function and antiviral or antitumor immunity — not neuroendocrine. The broader HPA-axis and fatigue literature does not implicate it either. Its mechanism is immunological, with no established link to cortisol or the stress axis. For this condition it is Grade D — unproven for stress or burnout because it has not been studied for it at all. On the regulatory side, in the U.S. thymosin alpha-1 was swept into the 2023 FDA compounding crackdown and was central to the Evexias/Farmakeio litigation; as of the 2026 PCAC schedule it was not among the peptides queued for the July 2026 Category 2 removal review, and the FDA has flagged compounded versions for immunogenicity and impurity concerns. Whatever its merits as an immune peptide, it is off-topic for 'adrenal fatigue' or stress resilience.
Strengths
- A genuine, well-characterized immune-modulating mechanism (T-cell and innate immunity)
- Established clinical use abroad in chronic hepatitis as an immune adjuvant
- Included here transparently to debunk its appearance on 'adrenal/energy' lists
Weaknesses
- No human or animal evidence whatsoever for stress, burnout, fatigue, cortisol or the HPA axis
- Mechanism is purely immunological with no established neuroendocrine link
- Not FDA-approved; FDA has flagged compounded versions for immunogenicity and impurity risk
- Best for
- Recognizing a peptide that does NOT belong on a stress or 'adrenal fatigue' list
- Pricing
- Not FDA-approved (sold abroad as thymalfasin/Zadaxin)
Feature comparison
| Feature | Selank | DSIP (Delta Sleep-Inducing Peptide / Emideltide) | Thymosin Alpha-1 (Tα1 / thymalfasin) |
|---|---|---|---|
| Controlled human trial | — | — | — |
| Animal evidence | — | — | — |
| Studied for this indication | — | — | — |
| Feature | Selank | DSIP (Delta Sleep-Inducing Peptide / Emideltide) | Thymosin Alpha-1 (Tα1 / thymalfasin) |
|---|---|---|---|
| Proposed target | — | — | — |
| Human cortisol effect confirmed | — | — | — |
| FDA-approved | — | — | — |
Frequently asked
Is 'adrenal fatigue' a real diagnosis I can treat with peptides?
No. A systematic review of 58 studies and the Endocrine Society both conclude 'adrenal fatigue' is not a validated medical condition, and the salivary cortisol-curve testing used to 'diagnose' it largely reflects sleep quality, not adrenal function. There is no peptide evidence for it because there is no validated condition or endpoint to test against. Persistent fatigue is real and worth investigating, but the cause is almost never the adrenal glands — it should be evaluated for true adrenal insufficiency, depression, thyroid disease, anemia, or sleep apnea by a licensed clinician rather than self-treated with a research peptide.
Which peptide has the best evidence for stress and fatigue?
Selank, by a wide margin — but only for diagnosed anxiety and asthenia, not 'adrenal fatigue.' A randomized comparative trial in 62 patients found Selank as effective as a benzodiazepine for generalized anxiety disorder, with an added antiasthenic (anti-fatigue) effect and no sedation or dependence, and an fMRI study showed it alters right-amygdala connectivity. The evidence is small, single-region (Russian) and unreplicated in Western RCTs, so it grades B — genuine human signal, but not the multi-RCT or meta-analysis tier. It was never studied in healthy stressed adults or for 'burnout,' so extrapolating it into a work-burnout cure is unsupported.
Doesn't DSIP lower cortisol and calm the stress axis?
In rodents, yes; in humans, the one controlled test said no. In rat stress models DSIP blunted stress-induced corticosterone and normalized disrupted hormone rhythms, which is the entire basis for the marketing. But when healthy young men were given intravenous DSIP versus placebo around CRH injections, their ACTH and cortisol responses were almost identical, and the authors concluded DSIP does not inhibit ACTH or cortisol secretion in man. The cortisol-lowering claim is therefore preclinical and specifically contradicted in people. Animal corticosterone effects do not transfer automatically to humans, which is exactly why this matters.
Why is thymosin alpha-1 on 'energy' and 'adrenal' peptide lists?
Likely marketing drift, not data. Thymosin alpha-1 is an immune-modulating peptide whose research base is immunological — T-cell function and antiviral or antitumor immunity — not neuroendocrine. Targeted searching returns no direct human or animal evidence linking it to chronic fatigue, the HPA axis, or cortisol, and the broader HPA-axis literature does not implicate it. Its appearance on 'vitality' or 'adrenal' lists appears to be category drift from general immune-optimization marketing rather than any stress-specific finding. For this condition it is Grade D — unproven because it has not been studied for it at all.
Are these peptides legal in the U.S. in 2026?
None is FDA-approved. After the 2023 Category 2 crackdown and subsequent litigation, the FDA (per an April 16, 2026 notice) is removing PCAC-bound peptides from Category 2 ahead of review meetings set for July 23–24, 2026 — but this does not legalize compounding, which still requires formal rulemaking. DSIP (Emideltide) is on the July 2026 review list; Selank and thymosin alpha-1 are not. In sport, all three plausibly fall under WADA's S0 catch-all for substances with no regulatory approval, so athletes and military personnel should treat them as prohibited and verify with their governing body.
If 'adrenal fatigue' is not real, what is actually causing my exhaustion?
The symptom cluster blamed on 'adrenal fatigue' — tiredness, poor sleep, salt or sugar cravings, caffeine dependence — is genuinely real, but the cause is almost never the adrenal glands. The Endocrine Society lists true culprits including real adrenal insufficiency, depression, obstructive sleep apnea, thyroid disease and anemia. Chronic stress also genuinely dysregulates the HPA axis, which is linked to anxiety, depression and ME/CFS. Chasing an 'adrenal' peptide fix risks missing those treatable diagnoses — and unneeded adrenal hormone supplements can suppress the glands and precipitate a life-threatening crisis on withdrawal, so evaluation by a clinician comes first.